455 related articles for article (PubMed ID: 26807602)
1. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Prebet T; Vey N
Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
[TBL] [Abstract][Full Text] [Related]
3. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
4. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
7. [Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome].
Zhi YQ; Guo SQ; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):792-5. PubMed ID: 22739204
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Quintás-Cardama A; Santos FP; Garcia-Manero G
Leukemia; 2011 Feb; 25(2):226-35. PubMed ID: 21116282
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
[TBL] [Abstract][Full Text] [Related]
11. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Glasser CL; Lee A; Eslin D; Marks L; Modak S; Glade Bender JL
J Pediatr Hematol Oncol; 2017 Oct; 39(7):560-564. PubMed ID: 28562519
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
14. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
Xu QY; Yu L
Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.
Voso MT; Lo-Coco F; Fianchi L
Curr Opin Oncol; 2015 Nov; 27(6):532-9. PubMed ID: 26352541
[TBL] [Abstract][Full Text] [Related]
16. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
[No Abstract] [Full Text] [Related]
17. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
Markozashvili D; Ribrag V; Vassetzky YS
Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf JP; Shallis RM; Sharon E; Park S; Ramaswamy R; Roe CE; Irish JM; Caldwell A; Wei W; Yacoub A; Madanat YF; Zeidner JF; Altman JK; Odenike O; Yerrabothala S; Kovacsovics T; Podoltsev NA; Halene S; Little RF; Piekarz R; Gore SD; Kim TK; Zeidan AM
Ann Hematol; 2024 Jan; 103(1):105-116. PubMed ID: 38036712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
